Progeneer Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Progeneer General Information

Description

Developer of immunotherapies and vaccines designed for the treatment of cancer and infectious diseases. The company utilizes a proprietary lipid nanotechnology platform to develop long-acting vaccine adjuvants with low toxicity and ease of formulation, enabling biotechnology companies and research institutes to access personalized cancer vaccines produced within few weeks timeframe and to utilize long-acting immunomodulators compatible with messenger ribonucleic acid vaccine formulations.

Contact Information

Website
www.progeneer.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12, Digital-ro 31-gil
  • Guro-gu
  • Seoul, 08380
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Vertical(s)
Nanotechnology, HealthTech, Life Sciences, Oncology
Corporate Office
  • 12, Digital-ro 31-gil
  • Guro-gu
  • Seoul, 08380
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Progeneer Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Generating Revenue
3. Later Stage VC (Series C) 26-Feb-2024 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Aug-2021 Completed Generating Revenue
1. Seed Round 08-Jul-2020 Completed Startup
To view Progeneer’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Progeneer Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Progeneer Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
HLB Investment Corporate Venture Capital Minority
Friend Investment Partners (Seoul) Venture Capital Minority
GB Ventures (Korea) Venture Capital Minority
Winvest Venture Capital Venture Capital Minority
To view Progeneer’s complete investors history, request access »

Ready to get started?

Request a free trial

Progeneer FAQs

  • When was Progeneer founded?

    Progeneer was founded in 2019.

  • Where is Progeneer headquartered?

    Progeneer is headquartered in Seoul, South Korea.

  • What is the size of Progeneer?

    Progeneer has 13 total employees.

  • What industry is Progeneer in?

    Progeneer’s primary industry is Biotechnology.

  • Is Progeneer a private or public company?

    Progeneer is a Private company.

  • What is Progeneer’s current revenue?

    The current revenue for Progeneer is .

  • Who are Progeneer’s investors?

    HLB Investment, Friend Investment Partners (Seoul), GB Ventures (Korea), and Winvest Venture Capital have invested in Progeneer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process